A Phase 3, Randomized, Double-blind Study of Duvelisib Administered in Combination With Rituximab and Bendamustine vs Placebo Administered in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma
Phase of Trial: Phase III
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Duvelisib (Primary) ; Bendamustine; Rituximab
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Haematological malignancies; Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms BRAVURA
- Sponsors Infinity Pharmaceuticals
- 28 Jun 2016 According to an Infinity Pharmaceuticals media release, the company has taken a strategic decision to close this trial.
- 28 Jun 2016 According to an Infinity Pharmaceuticals media release, status changed from recruiting to discontinued.
- 23 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.